Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

NCT05397639 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

375

Enrollment

INDUSTRY

Sponsor class

Conditions

Agitation
Alzheimer's Type Dementia

Interventions

DRUG: Masupirdine 50 mg
DRUG: Masupirdine 100 mg
DRUG: Placebo

Sponsor

Suven Life Sciences Limited